K. Kassahun et al., Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor, DRUG META D, 29(6), 2001, pp. 813-820
Etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, was shown to
be metabolized via 6'-methylhydroxylation (M2 formation) when incubated wi
th NADPH-fortified human liver microsomes. In agreement with in vivo data,
1'-N'-oxidation was a relatively minor pathway. Over the etoricoxib concent
ration range studied (1-1300 muM), the rate of hydroxylation conformed to s
aturable Michaelis-Menten kinetics (apparent K-m = 186 +/- 84.3 muM; V-max
= 0.76 +/- 0.45 nmol/min/mg of protein; mean +/- S.D., n = 3 livers) and yi
elded a V-max/K-m ratio of 2.4 to 7.3 mul/min/mg. This in vitro V-max/K-m r
atio was scaled, with respect to yield of liver microsomal protein and live
r weight, to obtain estimates of M2 formation clearance (3.1-9.7 ml/min/kg
of b.wt.) that agreed favorably with in vivo results (8.3 ml/min/kg of b.wt
.) following i.v. administration of [C-14]etoricoxib to healthy male subjec
ts. Cytochrome P450 (P450) reaction phenotyping studies-using P450 form sel
ective chemical inhibitors, immunoinhibitory antibodies, recombinant P450s,
and correlation analysis with microsomes prepared from a bank of human liv
ers-revealed that the 6'-methyl hydroxylation of etoricoxib was catalyzed l
argely (60%) by member(s) of the CYP3A subfamily. By comparison, CYP2C9 (si
milar to 10%), CYP2D6 (similar to 10%), CYP1A2 (similar to 10%), and possib
ly CYP2C19 played an ancillary role. Moreover, etoricoxib (0.1-100 muM) was
found to be a relatively weak inhibitor (IC50 > 100 muM) of multiple P450s
(CYP1A2, CYP2D6, CYP3A, CYP2E1, CYP2C9, and CYP2C19) in human liver micros
omes.